These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 12953081)

  • 1. Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.
    Bankhead C
    J Natl Cancer Inst; 2003 Sep; 95(17):1273-4. PubMed ID: 12953081
    [No Abstract]   [Full Text] [Related]  

  • 2. Bisphosphonates in prostate cancer: where are we and where should we go?
    Saad F
    J Natl Cancer Inst; 2003 Sep; 95(17):1262-3. PubMed ID: 12953073
    [No Abstract]   [Full Text] [Related]  

  • 3. Annual zoledronic acid: is less more?
    Higano CS
    J Clin Oncol; 2007 Mar; 25(9):1026. PubMed ID: 17369565
    [No Abstract]   [Full Text] [Related]  

  • 4. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
    [No Abstract]   [Full Text] [Related]  

  • 5. Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.
    Cai T; Bartoletti R
    J Clin Oncol; 2007 Aug; 25(22):3385; author reply 3385-6. PubMed ID: 17664492
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
    Miki T; Okihara K
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():632-5. PubMed ID: 18161177
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Winquist E; Berry S
    J Natl Cancer Inst; 2004 Aug; 96(15):1183; author reply 1183-1184. PubMed ID: 15292391
    [No Abstract]   [Full Text] [Related]  

  • 8. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
    Saad F; Abrahamsson PA; Miller K
    BJU Int; 2009 Dec; 104(11):1573-9. PubMed ID: 20053188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).
    Dearnaley DP; Sydes MR; Mason MD; Stott M; Powell CS; Robinson AC; Thompson PM; Moffat LE; Naylor SL; Parmar MK;
    J Natl Cancer Inst; 2003 Sep; 95(17):1300-11. PubMed ID: 12953084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer.
    Price N
    Clin Prostate Cancer; 2004 Sep; 3(2):77-9. PubMed ID: 15479488
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Tu SM; Lin SH; Logothetis C
    J Natl Cancer Inst; 2003 Aug; 95(15):1174-5; author reply 1175. PubMed ID: 12902452
    [No Abstract]   [Full Text] [Related]  

  • 12. Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say.
    Printz C
    Cancer; 2013 Sep; 119(17):3103-4. PubMed ID: 24037668
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
    Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
    J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Atkins CD
    J Natl Cancer Inst; 2003 Feb; 95(4):332; author reply 333-4. PubMed ID: 12591994
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Rosenthal M
    J Natl Cancer Inst; 2003 Feb; 95(4):332; author reply 333-4. PubMed ID: 12591992
    [No Abstract]   [Full Text] [Related]  

  • 16. [Current strategies of intermittent hormone therapy in prostate cancer].
    Kaprin AD; Pavlov AIu; Ivanov SA; Gafanov RA
    Vopr Onkol; 2011; 57(2):260-4. PubMed ID: 21809677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of bisphosphonates in the treatment of prostate cancer.
    Parker CC
    BJU Int; 2005 May; 95(7):935-8. PubMed ID: 15839907
    [No Abstract]   [Full Text] [Related]  

  • 18. Bone-targeted agents: preventing skeletal complications in prostate cancer.
    Morgans AK; Smith MR
    Urol Clin North Am; 2012 Nov; 39(4):533-46. PubMed ID: 23084529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients.
    Kachnic LA; Pugh SL; Tai P; Smith M; Gore E; Shah AB; Martin AG; Kim HE; Nabid A; Lawton CA
    Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):382-6. PubMed ID: 24080992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.
    Denham JW; Nowitz M; Joseph D; Duchesne G; Spry NA; Lamb DS; Matthews J; Turner S; Atkinson C; Tai KH; Gogna NK; Kenny L; Diamond T; Smart R; Rowan D; Moscato P; Vimieiro R; Woodfield R; Lynch K; Delahunt B; Murray J; D'Este C; McElduff P; Steigler A; Kautto A; Ball J
    BJU Int; 2014 Sep; 114(3):344-53. PubMed ID: 24512527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.